PDCD1 and neoplasm: For instance, phase III trials for patients with cholangiocarcinoma have been initiated in China (NCT03101488) to investigate Envafolimab, a first-in-class nanobody that binds with high affinity and specificity to PD-L1, blocking interaction with PD-1, and resulting in T cell-mediated immune response to neoplasms.